Sarepta Therapeutics Inc. (SRPT) CEO Sells $1,217,600.00 in Stock
Sarepta Therapeutics Inc. (NASDAQ:SRPT) CEO Edward M. Md Kaye sold 24,352 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,217,600.00. Following the completion of the sale, the chief executive officer now owns 89,983 shares of the company’s stock, valued at approximately $4,499,150. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) traded up 0.88% during midday trading on Wednesday, reaching $56.22. The company’s stock had a trading volume of 8,767,424 shares. The firm has a 50 day moving average price of $29.05 and a 200-day moving average price of $21.62. Sarepta Therapeutics Inc. has a 12-month low of $8.00 and a 12-month high of $58.87. The company’s market cap is $2.69 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the previous year, the business posted ($0.87) earnings per share. On average, equities research analysts predict that Sarepta Therapeutics Inc. will post ($4.17) earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/sarepta-therapeutics-inc-srpt-ceo-sells-1217600-00-in-stock.html
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning boosted its position in Sarepta Therapeutics by 2.3% in the first quarter. Creative Planning now owns 54,150 shares of the company’s stock worth $1,057,000 after buying an additional 1,200 shares in the last quarter. TIAA CREF Investment Management LLC boosted its position in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares in the last quarter. Franklin Resources Inc. acquired a new position in Sarepta Therapeutics during the first quarter worth approximately $13,506,000. BlackRock Fund Advisors boosted its position in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock worth $20,865,000 after buying an additional 25,799 shares in the last quarter. Hedge funds and other institutional investors own 72.09% of the company’s stock.
SRPT has been the subject of a number of recent research reports. Wedbush restated a “neutral” rating and issued a $14.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, May 25th. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Robert W. Baird reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $51.01.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.